Antiepileptic drugs and warfarin [1]

CMAJ. Canadian Medical Association Journal

Volumn 178, Issue 1, 2008, Pages 65-

  Ahmed, S Nizam ^a  

^a UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CYTOCHROME P450 ISOENZYME; PHENOBARBITAL; PHENYTOIN; WARFARIN;

BLEEDING; DRUG METABOLISM; ENZYME INDUCTION; EPILEPSY; HUMAN; LETTER; MENTAL DISEASE; MENTAL PATIENT; RISK FACTOR;

EID: 38349016259     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.1070121     Document Type: Letter

References (5)

1. Juurlink DN. Drug interactions with warfarin: what clinicians need to know. CMAJ 2007;177:369-71.
2. Herman D, Locatelli I, Grabnar I, et al. The influence of co-treatment with carbanmepine, amiodarone and statins on warfarin metabolism and maintenance dose. Eur J Clin Pharmacol 2006;62:291-6.
3. Solomom GE, Hilgartner MW, Kutt H. Coagulation defects caused by diphenylhydantoin. Neurology 1972;22:1165-71.
4. Nappi JM. Warfarin and phenytoin interactions. Ann Intern Med 1979;90:852.
5. Udall JA. Clinical implications of warfarin interactions with 5 sedatives. Am J Cardiol 1975;35:67-71.